Cellular response to hypoxia involves signaling via Smad proteins

Blood

Volumn 101, Issue 6, 2003, Pages 2253-2260

  Zhang, Hong ^b   Akman, Hasan O ^b   Smith, Eric L P ^b   Zhao, Jin ^b   Murphy Ullrich, Joanne E ^b   Siddiqui, M A Q ^b   Batuman, Olcay A ^a  

^a SUNY Downstate Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; AUTOCRINE EFFECT; CELL HYPOXIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR TRANSPORT; MOLECULAR INTERACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UMBILICAL VEIN; UPREGULATION;

EID: 0037443517     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0629     Document Type: Article

References (70)

1. Roberts AB, Sporn MB. The transforming growth factors-β. In: Sporn MB, Roberts AB, eds. Handbook of Experimental Pharmacology. Vol. 95/1. Peptide growth factors and their receptors. New York, NY: Springer Verlag; 1990:419-472.
2. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-351.
3. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development. 1995;121:1845-1854.
4. Oshima M, Oshima H, Taketo MM. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol. 1996;179:297-302.
5. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 1997;100:S61-S65.
6. Topper JN, Cai J, Qiu Y, et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A. 1997;94:9314-9319.
7. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development. 1997;124:2659-2670.
8. DiChiara MR, Kiely JM, Gimbrone MA Jr, Lee ME, Perrella MA, Topper JN. Inhibition of E-selectin gene expression by transforming growth factor β in endothelial cells involves coactivator integration of Smad and nuclear factor κB-mediated signals. J Exp Med. 2000;192:695-704.
9. Akman HO, Zhang H, Siddiqui MA, Solomon W, Smith ELP, Batuman OA. Response to hypoxia involves transforming growth factor-β2 and Smad proteins in human endothelial cells. Blood. 2001; 98:3324-3331.
10. Larsson J, Goumans MJ, Sjöstrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J. 2001;20:1663-1673.
11. Yang X, Li C, Xu X, Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A. 1998;95:3667-3672.
12. Yang X, Castilla LH, Xu X, et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development. 1999;126:1571-1580.
13. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol. 1993; 122:923-932.
14. Schultz-Cherry S, Chen H, Mosher DF, et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem. 1995;270:7304-7310.
15. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-β. J Biol Chem. 1999;274:13586-13593.
16. Lawler J. The functions of thrombospondin-1 and -2. Curr Opin Cell Biol. 2000;12:634-640.
17. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-betal in vivo. Cell. 1998;93:1159-1170.
18. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
19. Massagué J. TGF-β signal transduction. Annu Rev Biochem. 1998;67:753-791.
20. Sanchéz-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabéu C. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem. 2001;276:38527-38535.
21. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000;14:1983-1991.
22. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270:1230-1237.
23. 2 tension. Proc Natl Acad Sci U S A. 1995;92:5510-5514.
24. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997;272:22642-22647.
25. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998;95:7987-7992.
26. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem. 1999;274:6519-6525.
27. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A. 2000;97:4748-4753.
28. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
29. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
30. 2 sensing. Science. 2001; 292:464-468.
31. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature. 2002;417:975-978.
32. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun. 2002;296:343-349.
33. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins; identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
34. Gimbrone MA Jr. Culture of vascular endothelium. Prog Hemost Thromb. 1976;3:1-28.
35. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci U S A. 2001;98:4478-4485.
36. Mazzieri R, Munger JS, Rifkin DB. Measurement of active TGF-beta generated by cultured cells. Methods Mol Biol. 2000;142:13-27.
37. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 1994;216:276-284.
38. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
39. Batuman OA, Caro J, Schmidt RR, Hauptman SP. Macromolecular insoluble cold globulin (MICG): a marker for pluripotential hemopoietic stem cells. J Immunol. 1983;130:1051-1055.
40. O'Reilly MA, Geiser AG, Kim SJ, et al. Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-beta 2 promoter. J Biol Chem. 1992;267:19938-19943.
41. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-βresponses. Cell. 1998; 95:737-740.
42. Massagué J, Chen YG. Controlling TGF-β signaling. Genes Dev. 2000;14:627-644.
43. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11:72-82.
44. Beck I, Ramirez S, Weinmann R, Caro J. Enhancer element at the 3′-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem. 1991;266:15563-15566.
45. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 1995;4:357-362.
46. Phelan MW, Forman LW, Perrine SP, Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med. 1998;132:519-529.
47. Munger JS, Huang X, Kawakatsu H, et al. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-328.
48. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997;51:1376-1382.
49. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
50. Iruela-Arispe ML, Vazquez F, Ortega MA. Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann N Y Acad Sci. 1999;886:58-66.
51. Manganini M, Maier JA. Transforming growth factor beta2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration. Oncogene. 2000;19:124-133.
52. Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990;111:731-741.
53. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002;109:1551-1559.
54. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-βantagonist protects mice against metastasis without adverse side effects. J Clin Invest. 2002;109:1607-1615.
55. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999;84:1212-1222.
56. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21-43.
57. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol. 2000;217:42-53.
58. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999;104:1343-1351.
59. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
60. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394:485-490.
61. Brown JD, DiChiara MR, Anderson KR, Gimbrone MA, Topper JN. MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2mediated transcriptional activation in endothelial cells. J Biol Chem. 1999;274:8797-8805.
62. Scheid A, Wenger RH, Christina H, et al. Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. Pediatr Surg Int. 2000;16:232-236.
63. 3. J Clin Invest. 2000;105:577-587.
64. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-β-induced transcriptional activation. Genes Dev. 1998;12:2153-2163.
65. Pouponnot C, Jayaraman L, Massagué J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem. 1998;273:22865-22868.
66. Zhu H, Jackson T, Bunn HF. Detecting and responding to hypoxia. Nephrol Dial Transplant. 2002;17:3-7.
67. Ebert BL, Bunn HF. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol. 1998;18:4089-4096.
68. Lo RS, Massagué J. Ubiquitin-dependent degradation of TGF-β-activated Smad2. Nat Cell Biol. 1999;1:472-478.
69. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;17:5353-5362.
70. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001;86:23-33.